Oncogenic MicroRNAs: MiR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Sochor, Marek ^a   Basova, Petra ^b   Pesta, Michal ^b   Dusilkova, Nina ^b   Bartos, Jiri ^a   Burda, Pavel ^b   Pospisil, Vit ^b   Stopka, Tomas ^b  

^a REGIONAL HOSPITAL LIBEREC   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Breast cancer; Let 7a; microRNA; miR 155; miR 181b; miR 19a; miR 24

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; LET 7A; MICRORNA; MICRORNA 155; MICRORNA 181B; MICRORNA 19A; MICRORNA 24; UNCLASSIFIED DRUG; MIRN155 MICRORNA, HUMAN; MIRN181 MICRORNA, HUMAN; MIRN19 MICRORNA, HUMAN; MIRN24 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER SURGERY; CONTROLLED STUDY; EARLY CANCER; FEMALE; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; AGED; BLOOD; BREAST NEOPLASMS; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902301976     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-448     Document Type: Article

References (20)

1. Schwarzenbach H. Circulating nucleic acids as biomarkers in breast cancer. Breast Cancer Res 2013, 15(5):211.
2. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6(11):857-866.
3. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65(16):7065-7070.
4. Kim K, Chadalapaka G, Lee SO, Yamada D, Sastre-Garau X, Defossez PA, Park YY, Lee JS, Safe S. Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene 2012, 31(8):1034-1044.
5. Ouchida M, Kanzaki H, Ito S, Hanafusa H, Jitsumori Y, Tamaru S, Shimizu K. Novel direct targets of miR-19a identified in breast cancer cells by a quantitative proteomic approach. PLoS One 2012, 7(8):e44095.
6. Li S, Yang C, Zhai L, Zhang W, Yu J, Gu F, Lang R, Fan Y, Gong M, Zhang X, Fu L. Deep sequencing reveals small RNA characterization of invasive micropapillary carcinomas of the breast. Breast Cancer Res Treat 2012, 136(1):77-87.
7. Wu Q, Wang C, Lu Z, Guo L, Ge Q. Analysis of serum genome-wide microRNAs for breast cancer detection. Clini Chim Acta 2012, 413(13-14):1058-1065.
8. Song J, Bai Z, Han W, Zhang J, Meng H, Bi J, Ma X, Han S, Zhang Z. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci 2012, 57(4):897-904.
9. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 2010, 5(10):e13735.
10. Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 2008, 14(8):1539-1549.
11. Kim SJ, Shin JY, Lee KD, Bae YK, Sung KW, Nam SJ, Chun KH. MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res 2012, 14(1):R14.
12. Liu Y, Li H, Feng J, Cui X, Huang W, Li Y, Su F, Liu Q, Zhu J, Lv X, Chen J, Huang D, Yu F. Lin28 induces epithelial-to-mesenchymal transition and stemness via downregulation of Let-7a in breast cancer cells. PLoS One 2013, 8(12):e83083.
13. Cai WY, Wei TZ, Luo QC, Wu QW, Liu QF, Yang M, Ye GD, Wu JF, Chen YY, Sun GB, Liu YJ, Zhao WX, Zhang ZM, Li BA. The Wnt-beta-catenin pathway represses let-7 microRNA expression through transactivation of Lin28 to augment breast cancer stem cell expansion. J Cell Sci 2013, 126(Pt 13):2877-2889.
14. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF, Wang ED. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010, 70(8):3119-3127.
15. Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, Li J. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One 2012, 7(10):e47003.
16. Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, Brown M, Hafner M, Reyal F, van Kouwenhove M, Kreike B, Sie D, Hovestadt V, Wessels LF, van de Vijver MJ, Tuschl T. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res 2011, 71(13):4443-4453.
17. Bisso A, Faleschini M, Zampa F, Capaci V, De Santa J, Santarpia L, Piazza S, Cappelletti V, Daidone M, Agami R, Del Sal G. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle 2013, 12(11):1679-1687.
18. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010, 39(4):493-506.
19. Papadimitriou E, Vasilaki E, Vorvis C, Iliopoulos D, Moustakas A, Kardassis D, Stournaras C. Differential regulation of the two RhoA-specific GEF isoforms Net1/Net1A by TGF-beta and miR-24: role in epithelial-to-mesenchymal transition. Oncogene 2012, 31(23):2862-2875.
20. Eichelser C, Flesch-Janys D, Chang-Claude J, Pantel K, Schwarzenbach H. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem 2013, 59(10):1489-1496.